Coexya, a company supported by Argos Wityu, is to acquire Aquilab.

The acquisition will enable Coexya to strengthen its leadership position in healthcare and more specifically in oncology.

Lyon (France), 25 April 2022 – Coexya, an independent digital leader in consulting, integration and software development, is to acquire Aquilab, a software company specialised in healthcare. The transaction will be a strategic merger of the two companies, enabling them to pursue their development.

Based in northern France, Aquilab has been a recognised software provider in the field of oncology for more than 20 years. Aquilab’s range of software and services improves the quality of treatment:
• Artiscan ensures the quality of imaging and radiotherapy equipment.
• Artiview improves the preparation and evaluation of radiotherapy treatment.
• Onco Place, evaluates and identifies new therapeutic strategies for its 3,300 users through the analysis of its clinical study database.

Both companies are strong in healthcare and oncology data. The merger will take advantage of their complementary nature and enable them to create multi-centric clinical studies. Coexya will use its Consore solution to create cohorts of patients, while Aquilab will use Onco Place to manage clinical studies.

Coexya will be able to share its expertise with Aquilab’s 350 European customers, and Aquilab will be able to accelerate its product development thanks to Coexya’s recognised expertise in data processing and artificial intelligence.

Formerly the French arm of the Sword group, Coexya was acquired by Argos Wityu in 2021, and has since then implemented an acquisition strategy to develop its product division and its international presence.

Healthcare accounts for 15% of Coexya’s activities. The company provides the sector with its OdyCare software and its integration services. Coexya understands the challenges its customers face and supports them in their digital transition. Their appropriate, ergonomic solutions make it easier to offer coordinated care, to guide patients and get more value from its patient data.

Philippe le Calvé, CEO of Coexya, said, “I am particularly pleased that Coexya is acquiring Aquilab, a company active in the healthcare sector. Our customers will be able to take advantage of an expanded range of services in France and abroad. We are delighted to welcome Aquilab’s employees into our group through a transaction that will also enable us to develop in the region of Lille.

David Gibon, Aquilab’s chief executive, said, “For more than 20 years, we have been providing innovative products devoted to improving the quality of cancer treatment. The merger with Coexya will enable us to strengthen our expertise in data and AI so as to step up our development in predictive medicine. Aquilab and Coexya have customers in common and share the same values. By leveraging these synergies, we will be able to propose new solutions and provide better treatment to people suffering from cancer.”

Karel Kroupa, Argos Wityu Managing Partner, added, “The merger between Aquilab and Coexya is right in line with the group’s business development strategy, as employed by Philippe Le Calvé and his team. Coexya will now be able to use the expertise of the two companies to offer complementary services to its customers.”